title: Dronedarone.
abstract: Oral dronedarone is a non-iodinated benzofurane derivative structurally related to amiodarone. Although it is considered a class III antiarrhythmic agent like amiodarone, it demonstrates multi-class electrophysiological activity. Data from the ATHENA study demonstrated that patients receiving oral dronedarone 400 mg twice daily for 12-30 months had a significantly lower risk of experiencing first hospitalization due to a cardiovascular event or death from any cause than those receiving placebo. Dronedarone exhibited rate- and rhythm-controlling properties in patients with atrial fibrilation (AF) or atrial flutter, significantly reducing the risk of a first recurrence of AF versus placebo following 12 months' therapy in the ADONIS and EURIDIS studies. In the ERATO study, dronedarone was also significantly more effective than placebo in terms of ventricular rate control. Furthermore, the beneficial effects of oral dronedarone on ventricular rate control were maintained during exercise and sustained with continued therapy. Oral dronedarone was generally well tolerated in the treatment of adult patients with AF and/or atrial flutter in clinical studies. The incidence of diarrhoea, nausea, bradycardia, rash and QT-interval prolongation was significantly higher with oral dronedarone than placebo in the large ATHENA study; however, serious cardiac-related adverse events were observed in <1% of oral dronedarone recipients.
authors.affiliation: Wolters Kluwer Health/Adis, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Sheridan M
authors.initials: SM
authors.lastname: Hoy
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Keam
mesh_terms: D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000503:physiopathology; D000077764:Dronedarone; D004347:Drug Interactions; D006801:Humans; D007408:Intestinal Absorption; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic
chemical_list: D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone
references.citation: Fundam Clin Pharmacol. 2004 Feb;18(1):113-23
references.pmid: 14748763
references.citation: N Engl J Med. 2008 Jun 19;358(25):2678-87
references.pmid: 18565860
references.citation: J Cardiovasc Pharmacol. 2003 Feb;41(2):191-202
references.pmid: 12548079
references.citation: Br J Clin Pharmacol. 2007 Dec;64(6):785-91
references.pmid: 17662087
references.citation: Eur J Endocrinol. 2007 Jun;156(6):695-702
references.pmid: 17535870
references.citation: N Engl J Med. 2007 Sep 6;357(10):987-99
references.pmid: 17804843
references.citation: J Pharmacol Exp Ther. 2000 Jan;292(1):415-24
references.pmid: 10604978
references.citation: J Cardiovasc Pharmacol. 2000 Dec;36(6):802-5
references.pmid: 11117382
references.citation: Eur J Pharmacol. 2004 Aug 2;496(1-3):119-27
references.pmid: 15288583
references.citation: Drug Saf. 2002;25(12):847-65
references.pmid: 12241126
references.citation: J Cardiovasc Pharmacol. 2001 Oct;38(4):500-11
references.pmid: 11588520
references.citation: Med Clin North Am. 2008 Jan;92(1):121-41, xi
references.pmid: 18061001
references.citation: Lancet. 2007 Aug 18;370(9587):604-18
references.pmid: 17707756
references.citation: J Cardiovasc Pharmacol Ther. 2007 Sep;12(3):248-57
references.pmid: 17875953
references.citation: Am Heart J. 2008 Sep;156(3):527.e1-9
references.pmid: 18760136
references.citation: J Cardiovasc Pharmacol Ther. 2007 Mar;12(1):15-26
references.pmid: 17495254
references.citation: J Cardiovasc Pharmacol Ther. 2006 Sep;11(3):184-90
references.pmid: 17056831
references.citation: J Cardiovasc Pharmacol. 1999 Feb;33(2):212-22
references.pmid: 10028928
references.citation: Eur Heart J. 2003 Aug;24(16):1481-7
references.pmid: 12919771
references.citation: J Cardiovasc Pharmacol Ther. 2007 Dec;12(4):314-21
references.pmid: 18172226
references.citation: N Engl J Med. 2009 Feb 12;360(7):668-78
references.pmid: 19213680
references.citation: Br J Pharmacol. 2000 Jul;130(6):1315-20
references.pmid: 10903971
references.citation: Br J Pharmacol. 2001 Jul;133(5):625-34
references.pmid: 11429385
references.citation: J Cardiovasc Pharmacol. 2000 Sep;36(3):376-83
references.pmid: 10975596
references.citation: Br J Pharmacol. 2003 Nov;140(5):996-1002
references.pmid: 14517175
references.citation: J Cardiovasc Pharmacol. 1995 Sep;26(3):453-61
references.pmid: 8583788
references.citation: Eur J Pharmacol. 1995 Jun 6;279(1):25-32
references.pmid: 7556379
references.citation: Circulation. 1999 Nov 30;100(22):2276-81
references.pmid: 10578003
references.citation: J Cardiovasc Pharmacol. 1995 Feb;25(2):252-61
references.pmid: 7752650
references.citation: J Cardiovasc Pharmacol. 1995 Oct;26(4):570-6
references.pmid: 8569217
references.citation: J Cardiovasc Electrophysiol. 2003 Aug;14(8):885-90
references.pmid: 12890054
references.citation: N Engl J Med. 2009 Apr 30;360(18):1811-3
references.pmid: 19403901
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):371-6
references.pmid: 18392809
references.citation: J Cardiovasc Electrophysiol. 2008 Jan;19(1):69-73
references.pmid: 18031520
references.citation: Eur J Pharmacol. 2002 May 31;444(3):191-6
references.pmid: 12063079
references.citation: J Cardiovasc Pharmacol. 2002 May;39(5):677-84
references.pmid: 11973411
references.citation: Curr Med Chem. 2006;13(14):1635-53
references.pmid: 16787210